AD patients have increased glutamate and one of the ways the BBB is disrupted in AD patients is with reduced GLUT1 expression, but the GLUT1 stimulator ceftriaxone has been shown to improve hippocampal memory and synaptic plasticity impairment in AD model mice [138, 139]. Here, SLC2A1 is linked to Alzheimer disease.